ClinConnect ClinConnect Logo
Search / Trial NCT06873568

Cephalic Femoral Heads Follow Up

Launched by LIMACORPORATE S.P.A · Mar 11, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Femoral Head Partial Hip Arthroplasty

ClinConnect Summary

The Cephalic Femoral Heads Follow Up clinical trial is studying the safety and effectiveness of a specific type of hip implant called cephalic femoral heads. This trial is for people who have had a hip replacement surgery due to a certain type of hip fracture known as a displaced intracapsular hip fracture. If you are between the ages of 65 and 74, have had this type of surgery since January 1, 2023, and can walk independently, you might be eligible to participate.

During the trial, participants will be monitored to see how well the implants work and if they are safe for use. It’s important to note that people with certain conditions, such as less severe fractures or severe arthritis, and those who cannot walk before surgery, will not be included in the study. If you decide to participate, you will be contributing valuable information that could help improve future hip surgeries for others. The study is not yet recruiting participants but will focus on those who meet the criteria and are willing to take part in this important research.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Displaced intracapsular hip fracture (Garden III-IV).
  • Subjects underwent a Unipolar Hemiarthroplasty with a Cephalic femoral head as per their Indication For Use from January 1st, 2023, onwards.
  • No concurrent joint disease at the time of the surgery.
  • Absence of severe cognitive dysfunction demonstrated by 3 or more correct answers on the Pfeiffer test.
  • Ability to ambulate independently with or without walking aids before surgery.
  • Subject willingness to participate.
  • Exclusion Criteria:
  • Undisplaced or minimally displaced intracapsular hip fracture (Garden I-II).
  • Any Cephalic femoral head contraindication for use as reported in the current Instruction For Use.
  • Pathological fracture secondary to malignant disease.
  • Subjects with rheumatoid arthritis or symptomatic osteoarthritis.
  • Previous treatment to the same hip for a fracture at the time of the surgery.
  • Subjects who were deemed unsuitable for the surgical procedures by the anesthesiologist.
  • Severe cognitive dysfunction or cognitive impairment demonstrated by 2 or less correct answers on the Pfeiffer test.
  • Unable to walk before surgery (e.g., wheelchair or bed-ridden subjects).

About Limacorporate S.P.A

Limacorporate S.p.A. is a leading global medical device company specializing in innovative solutions for orthopedic surgery and regenerative medicine. With a strong commitment to research and development, Limacorporate focuses on advancing surgical techniques and improving patient outcomes through its cutting-edge technologies and products. The company is dedicated to conducting rigorous clinical trials to ensure the safety and efficacy of its offerings, fostering collaboration with healthcare professionals and institutions worldwide to enhance the standard of care in musculoskeletal treatments.

Locations

Presov, , Slovakia

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported